The bill was introduced by 2 Republicans and 2 Democrats and would direct HHS to undertake a study to understand how substitution of interchangeable biologic products may be impeded.
While the United States has an increasing number of approved biosimilars, uptake of these less costly alternatives to biologics has been uneven and slow. A new bill introduced in the House of Representatives seeks to evaluate the current challenges to substituting biologics with biosimilars with the purpose of making biosimilars more accessible.
The Biologics Competition Act of 2022 (HR 887) was introduced by Representatives Mariannette Miller-Meeks, MD, R-Iowa; Greg Murphy, MD, R-North Carolina; Nanette Barragán, D-California; and Ann Kuster, D-New Hampshire.
“As pharmaceutical prices continue to skyrocket, we must do everything in our power to make lifesaving drugs more affordable for those in need,” Miller-Meeks said in a statement. “Our bill will encourage the Department of Health and Human Services to expedite the approval process for biosimilar products which may be used interchangeably in place of more expensive drugs.”
There are currently 38 biosimilars approved in the United States, although only 22 have launched so far. The biologic with the most approved biosimilars is adalimumab (Humira); however, none of these have launched yet due to settlement agreements. The first adalimumab biosimilar will reach market in January 2023.
Of the approved biosimilars, there are 3 with interchangeability status, which means the product may be substituted for its reference product without intervention of the prescriber. A biosimilar with interchangeability is not any more effective than a biosimilar without the designation, although that is a source of confusion and an area of necessary education for health care providers.
The bill directs the secretary of HHS within 1 year if the bill is passed into law to complete a study evaluating how substitution of interchangeable biologic products may be impeded. A report will be submitted to Congress on the results of the study.
In addition, HHS is directed to update the list published in the Purple Book. The Purple Book is a searchable, online database that contains information about biological products updated by the FDA for users to see if biologic products have been deemed biosimilar to or interchangeable with a reference biologic product.
The update to the Purple Book should align communication of substitutability of interchangeable products with communication about therapeutic equivalence ratings, according to the text of the bill.
“At a time when Americans are struggling to afford the escalating prices for prescription drugs, bureaucracy can’t get in the way of Americans accessing life-saving medicines,” said Barragán. “I am proud to join Reps. Miller-Meeks, Murphy, and Kuster in working to make biosimilars more accessible and affordable to the American people. Our bill will make HHS take a closer look at the unnecessary hurdles that delay access to innovative biosimilars and report back to Congress. Interchangeable biologics can reduce drug costs, and this bill takes an important step forward to ensure they are accessible to patients.”
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More